mirtazapine has been researched along with Psychomotor Agitation in 6 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Psychomotor Agitation: A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This parallel-group, double-blind, placebo-controlled trial-the Study of Mirtazapine for Agitated Behaviours in Dementia trial (SYMBAD)-was done in 26 UK centres." | 9.41 | Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. ( Ballard, C; Banerjee, S; Bentham, P; Burns, A; Farina, N; Fox, C; Francis, P; Henderson, C; High, J; Howard, R; Knapp, M; Leroi, I; Livingston, G; Nilforooshan, R; Nurock, S; O'Brien, J; Price, A; Shepstone, L; Stirling, S; Swart, AM; Tabet, N; Telling, T; Thomas, AJ, 2021) |
| "A 23-year-old man with a history of alcohol dependence was admitted to our hospital after self-intoxication with 2700 mg baclofen and 330 mg mirtazapine." | 5.43 | [Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms]. ( de Witte, LD; Dekker, D; Kaasjager, K; Kromkamp, M; Veraart, J; Vinkers, CH, 2016) |
| "This parallel-group, double-blind, placebo-controlled trial-the Study of Mirtazapine for Agitated Behaviours in Dementia trial (SYMBAD)-was done in 26 UK centres." | 5.41 | Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. ( Ballard, C; Banerjee, S; Bentham, P; Burns, A; Farina, N; Fox, C; Francis, P; Henderson, C; High, J; Howard, R; Knapp, M; Leroi, I; Livingston, G; Nilforooshan, R; Nurock, S; O'Brien, J; Price, A; Shepstone, L; Stirling, S; Swart, AM; Tabet, N; Telling, T; Thomas, AJ, 2021) |
| "Antipsychotic-induced akathisia is optimally managed by reducing the medication dose or switching to a second generation antipsychotic that is less prone to inducing akathisia." | 2.72 | Struggling to find Effective Pharmacologic Options for Akathisia? B-CALM! ( Birur, B; Fargason, RE; Thippaiah, SM, 2021) |
| "Mirtazapine-treated patients demonstrated a statistically significant (p < or = ." | 2.40 | A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. ( Barkin, RL; Fawcett, J, 1998) |
| "A 23-year-old man with a history of alcohol dependence was admitted to our hospital after self-intoxication with 2700 mg baclofen and 330 mg mirtazapine." | 1.43 | [Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms]. ( de Witte, LD; Dekker, D; Kaasjager, K; Kromkamp, M; Veraart, J; Vinkers, CH, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, S | 1 |
| High, J | 1 |
| Stirling, S | 1 |
| Shepstone, L | 1 |
| Swart, AM | 1 |
| Telling, T | 1 |
| Henderson, C | 1 |
| Ballard, C | 1 |
| Bentham, P | 1 |
| Burns, A | 1 |
| Farina, N | 1 |
| Fox, C | 1 |
| Francis, P | 1 |
| Howard, R | 1 |
| Knapp, M | 1 |
| Leroi, I | 1 |
| Livingston, G | 1 |
| Nilforooshan, R | 1 |
| Nurock, S | 1 |
| O'Brien, J | 1 |
| Price, A | 1 |
| Thomas, AJ | 1 |
| Tabet, N | 1 |
| Naguy, A | 1 |
| Moodliar-Rensburg, S | 1 |
| Alamiri, B | 1 |
| Thippaiah, SM | 1 |
| Fargason, RE | 1 |
| Birur, B | 1 |
| de Witte, LD | 1 |
| Dekker, D | 1 |
| Veraart, J | 1 |
| Kromkamp, M | 1 |
| Kaasjager, K | 1 |
| Vinkers, CH | 1 |
| Fawcett, J | 1 |
| Barkin, RL | 2 |
| Davis, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pragmatic, Multi Centre, Double-blind, Placebo Controlled Randomised Trial to Assess the Safety, Clinical and Cost Effectiveness of Mirtazapine in Patients With Alzheimer's Disease (AD) and Agitated Behaviours[NCT03031184] | Phase 3 | 207 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mirtazapine and Psychomotor Agitation
| Article | Year |
|---|---|
Struggling to find Effective Pharmacologic Options for Akathisia? B-CALM!
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Humans; Mirtazapine; Propranolol; Psychomotor Agitati | 2021 |
A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Depress | 1998 |
1 trial available for mirtazapine and Psychomotor Agitation
| Article | Year |
|---|---|
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.
Topics: Aged, 80 and over; Anti-Anxiety Agents; Brief Psychiatric Rating Scale; Caregivers; Dementia; Double | 2021 |
3 other studies available for mirtazapine and Psychomotor Agitation
| Article | Year |
|---|---|
Mirtazapine Treatment for Azithromycin-Associated Akathisia.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Azithromycin; Humans; Mirtazapine; Psychomotor Agitat | 2020 |
[Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms].
Topics: Adult; Aggression; Alcoholism; Baclofen; Delirium; Drug Overdose; GABA-B Receptor Agonists; Humans; | 2016 |
Clinical pharmacology of mirtazapine: revisited.
Topics: Agranulocytosis; Antidepressive Agents, Tricyclic; Anxiety; Depression; Humans; Mianserin; Mirtazapi | 1999 |